Pacira BioSciences, Inc.
PCRX
$26.30
$0.311.19%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.85M | 4.81M | 16.04M | -143.47M | 18.89M |
| Total Depreciation and Amortization | 27.32M | 21.17M | 21.24M | 20.25M | 18.86M |
| Total Amortization of Deferred Charges | 872.00K | 867.00K | 868.00K | 863.00K | 786.00K |
| Total Other Non-Cash Items | 26.87M | 7.39M | 19.31M | 174.18M | 19.09M |
| Change in Net Operating Assets | -38.20M | 1.22M | -24.33M | 2.09M | -4.39M |
| Cash from Operations | 12.01M | 35.46M | 33.13M | 53.92M | 53.24M |
| Capital Expenditure | -2.70M | -8.55M | -2.12M | -4.09M | -1.59M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | -16.70M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 64.86M | -379.00K | 1.75M | -48.07M | -13.63M |
| Cash from Investing | 62.16M | -25.63M | -368.00K | -52.16M | -15.22M |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 287.50M |
| Total Debt Repaid | -3.75M | -2.81M | -2.81M | -2.81M | -202.45M |
| Issuance of Common Stock | 1.57M | -- | 934.00K | 0.00 | 1.36M |
| Repurchase of Common Stock | -55.32M | -181.00K | -77.00K | -32.00K | -25.38M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | -36.06M |
| Cash from Financing | -57.51M | -2.99M | -1.96M | -2.85M | 24.98M |
| Foreign Exchange rate Adjustments | 204.00K | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.87M | 6.84M | 30.81M | -1.09M | 63.00M |